Hormonal
Despite high rates of medical treatment (89.1% of diagnosed diabetics), glycemic control remains poor, with only 23.3% achieving the target HbA1c <6.5% and 43.5% achieving <7.0%.
Just because you are taking diabetes medication doesn't mean your blood sugar is under control. Only about 1 in 4 people achieve the strict target of HbA1c <6.5%. You need to check your HbA1c regularly to ensure your treatment plan is actually working.
Although most subjects with diabetes (89.1%) were under medical treatment, and mostly being treated with oral hypoglycemic agents (80.2%), 10.8% have remained untreated. With respect to overall glycemic control, 43.5% reached the target of HbA1c <7%, whereas 23.3% reached the target when the standard was set to HbA1c <6.5%, according to the Korean Diabetes Association guideline.
Why this rating
Large sample size and objective biomarker (HbA1c) measurement, but cross-sectional nature prevents determining if poor control is due to non-adherence, inadequate dosing, or disease progression.
Source
Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status
Jong Chul Won et al. · Diabetes & Metabolism Journal · 2018
DOI 10.4093/dmj.2018.0017
More from this paper
- In Korean adults aged 30 and older, diabetes prevalence is 13.7% (4.8 million) and impaired fasting glucose (prediabetes) prevalence is 24.8% (8.3 million), with prevalence increasing significantly with age and lower family income.Good
- Comorbidities including obesity (48.6%), hypertension (54.7%), and hypercholesterolemia (31.6%) are highly prevalent in Korean adults with diabetes, yet control rates for these conditions are suboptimal.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →